The Telix (ASX:TLX) share price is on the move today. Here’s why.

The Telix Pharmaceuticals (ASX: TLX) share price has dipped on open today despite a positive development in the company’s lead drug candidate.
The post The Telix (ASX:TLX) share price is on the move today. Here’s why. appeared first on The Motley Fool Australia. –

close up of man's eye looking through magnifying glass representing asx 200 share price on watch

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is trading lower at open today, despite a positive development in its lead drug candidate. Telix announced that the United States Food and Drug Administration (FDA) will begin reviewing its new drug application (NDA) for TLX591-CDx.

At the time of writing, the Telix share price has dipped 0.8% to $3.72.

FDA progress

Telix advised the market today that the US FDA has deemed that the company’s NDA for TLX591-CDx is sufficient, and will begin a formal review.

During the standard review process, the FDA will conduct a mid-cycle review meeting date with Telix. This engagement seeks to discuss the status of the drug, key findings, and any issues that are identified. Telix revealed that the meeting will take place on 16 February 2021.

In addition, a label review date with the FDA will follow, with the date set on 30 May 2021. In the meeting, a team of technical experts will look to verify that the correct labelling meets FDA regulations.

Telix also said the FDA has provided intermediate milestones for the review process, and that no major issues have been found so far. In light of this, the FDA does not plan to hold an advisory committee meeting to discuss the application.

While Telix progresses with the FDA, the company is also focusing its efforts in the European Union, Canada and Australia. Telix advised it is moving along with its marketing authorisation application which has been submitted to authorities.

What did management say?

Telix CEO Dr Christian Behrenbruch welcomed the progress, saying:

With proximal review timelines for our NDA submission and considering the recent limited approval of Ga-PSMA for both imaging of high risk men prior to prostatectomy and biochemical recurrence, we feel our package is in a strong position to complete review in a timely fashion.

Telix’s kit-based formulation of Ga-PSMA is a game changer in terms of delivering access to this important technology and we look forward to working with the FDA to conclude the technical and clinical review of our submission during 2021.

About the Telix share price

The Telix share price has been storming higher lately due to a raft of announcements from the company. In just over a month, its shares have lifted more than 70%.

The Telix share price reached an all-time high of $4.33 this month, and finished the day yesterday at $3.75.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of June 30th

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post The Telix (ASX:TLX) share price is on the move today. Here’s why. appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!